Want to learn more about joining us in research?

Institute for Neurodegenerative Disorders
Institute for Neurodegenerative Disorders
  • Home
  • About Us
    • The Institute
    • Leadership Team
  • Participate
    • How To Participate
    • Clinical Trials
    • Active Studies
  • Resources
    • Neurologic Conditions
    • Parkinson Disease
    • Alzheimer Disease
    • Huntington Disease
    • Brain Imaging
    • Imaging in Alzheimer
    • Imaging in Parkinson
    • General Resources
  • Contact Us
  • Directions
  • Donate
  • More
    • Home
    • About Us
      • The Institute
      • Leadership Team
    • Participate
      • How To Participate
      • Clinical Trials
      • Active Studies
    • Resources
      • Neurologic Conditions
      • Parkinson Disease
      • Alzheimer Disease
      • Huntington Disease
      • Brain Imaging
      • Imaging in Alzheimer
      • Imaging in Parkinson
      • General Resources
    • Contact Us
    • Directions
    • Donate
  • Sign In
  • Create Account

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out

Signed in as:

filler@godaddy.com

  • Home
  • About Us
    • The Institute
    • Leadership Team
  • Participate
    • How To Participate
    • Clinical Trials
    • Active Studies
  • Resources
    • Neurologic Conditions
    • Parkinson Disease
    • Alzheimer Disease
    • Huntington Disease
    • Brain Imaging
    • Imaging in Alzheimer
    • Imaging in Parkinson
    • General Resources
  • Contact Us
  • Directions
  • Donate

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

Imaging in Parkinson Disease

Over the past decade researchers at IND have developed and utilized dopamine transporter imaging in several studies to evaluate the diagnosis and monitor progression of Parkinson disease. In our studies, dopamine transporter imaging using SPECT discriminated between individuals with Parkinson disease and healthy subjects with a sensitivity of about 98%.


In addition to dopamine transporter imaging, several other imaging modalities evaluating neurochemical systems are under development. Neurochemical changes other than dopamine may be responsible for the non-motor symptoms of Parkinson disease including depression, anxiety, sleep difficulties and change in cognition. Understanding these neurochemical changes in the brain offers the opportunity to develop medications to improve both the motor and non-motor symptoms that occur in Parkinson disease.

  • Home
  • Contact Us
  • Donate
  • Privacy Policy
  • FCOI Policy

Institute for Neurodegenerative Disorders

60 Temple Street, Suite 8B, New Haven, Connecticut 06510, United States

Copyright © 2023 IND - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept